<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03557957</url>
  </required_header>
  <id_info>
    <org_study_id>HIT-trial</org_study_id>
    <nct_id>NCT03557957</nct_id>
  </id_info>
  <brief_title>Targeted Correction of Plasma Sodium Levels in Hospitalized Patients With Hyponatremia</brief_title>
  <acronym>HIT</acronym>
  <official_title>Targeted Correction of Plasma Sodium Levels in Hospitalized Patients With Hyponatremia: a Randomized, Controlled, Parallel-group Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cantonal Hospital of Aarau, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Luzerner Kantonsspital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kantonsspital St. Gallen, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kantonsspital Liestal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Antonius Ziekenhuis Nieuwegein, The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyponatremia is the most common electrolyte disorder with a prevalence of up to 30% in
      hospitalized patients. While treatment of acute hyponatremia with severe clinical symptoms
      due to cerebral edema is undisputed and straightforward, hyponatremia in general is usually
      considered asymptomatic or not clinically relevant. Accordingly, a recent observational study
      showed that appropriate laboratory tests to evaluate the etiology of hyponatremia were
      obtained in less than 50% of patients, leading to 75% of patients being still hyponatremic at
      discharge.

      This is problematic in the context of increasing evidence, revealing an association of
      chronic hyponatremia with adverse effects such as gait alterations and falls, attention
      deficits, bone loss and fractures as well as disease-associated morbidity leading to
      increased rates of readmissions and mortality. Yet, there is a complete lack of randomized
      clinical trials with the primary aim to investigate whether correction of plasma sodium
      concentration counteracts the elevated risk of rehospitalization and mortality.

      The aim of this trial is therefore to determine the effects on mortality and
      rehospitalization rate of a targeted correction of plasma sodium concentration in addition to
      current standard care in hospitalized hyponatremic patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, controlled, parallel-group trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcome assessors will be blinded to allocated treatment group</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is the combined risk of death or rehospitalization within 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of death or rehospitalization within 30 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30 days mortality rate</measure>
    <time_frame>30 days</time_frame>
    <description>Mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year mortality rate</measure>
    <time_frame>1 year</time_frame>
    <description>Mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 days rehospitalization rate</measure>
    <time_frame>30 days</time_frame>
    <description>Rehospitalization rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year rehospitalization rate</measure>
    <time_frame>1 year</time_frame>
    <description>Rehospitalization rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to rehospitalization</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Days until first rehospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Days until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospital stay</measure>
    <time_frame>up to 1 year</time_frame>
    <description>length of index hospital stay in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of falls</measure>
    <time_frame>30 days</time_frame>
    <description>Number of falls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of fractures</measure>
    <time_frame>30 days</time_frame>
    <description>Number of bone fractures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of fractures</measure>
    <time_frame>1 year</time_frame>
    <description>Number of bone fractures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Plasma sodium normalization at discharge</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Rate of Plasma sodium Levels &gt;=135mmol/L at discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma sodium Levels</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Change in mmol/L in Plasma sodium Levels from inclusion to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of hyponatremia</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of recurrence of hyponatremia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of hyponatremia</measure>
    <time_frame>1 year</time_frame>
    <description>Rate of recurrence of hyponatremia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severely symptomatic hyponatremia</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Rate of severely symptomatic hyponatremia requiring intensive care Treatment during index hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium-overcorrection</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Rate of plasma sodium overcorrection during index hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Rate of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of severe adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Rate of severe adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy of copeptin in the diagnosis of hyponatremia</measure>
    <time_frame>1 day</time_frame>
    <description>Copeptin Level will be correlated with final hyponatremia diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy of mid-regional mid-regional (MR)-proANP in the diagnosis of hyponatremia</measure>
    <time_frame>1 day</time_frame>
    <description>MR-proANP Level will be correlated with final hyponatremia diagnosis N-terminal (NT)-proBNP, aldosterone, renin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy of NT-proBNP in the diagnosis of hyponatremia</measure>
    <time_frame>1 day</time_frame>
    <description>NT-proBNP Level will be correlated with final hyponatremia diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy of aldosterone in the diagnosis of hyponatremia</measure>
    <time_frame>1 day</time_frame>
    <description>Aldosterone Level will be correlated with final hyponatremia diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy of renin in the diagnosis of hyponatremia</measure>
    <time_frame>1 day</time_frame>
    <description>Renin Level will be correlated with final hyponatremia diagnosis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2278</enrollment>
  <condition>Hyponatremia</condition>
  <arm_group>
    <arm_group_label>Standard care plus targeted correction of hyponatremia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diagnosis and treatment of hyponatremia will be standardized according to the European Clinical Practice Guidelines (ECPG). Treatment response and adherence will be evaluated daily and treatment adapted if treatment goals are not reached.Targeted correction of plasma sodium Levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diagnosis and treatment of hyponatremia will be solely at the discretion of the attending physicians who are in no way involved in the trial. The study team will not intervene with the treatment in any way. Diagnostic and treatment decisions as well as course of the plasma sodium level will only be recorded after patient is discharged from hospital using the medical records and patient charts. It will be generally recommended to measure plasma sodium levels 3x weekly or more frequently if clinically indicated, at discharge and after 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Targeted correction of plasma sodium levels</intervention_name>
    <description>Targeted correction of hyponatremia</description>
    <arm_group_label>Standard care plus targeted correction of hyponatremia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>Standard care of hyponatremia</description>
    <arm_group_label>Standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adult hospitalised patients with hypotonic hyponatremia &lt;130mmol/L

        Exclusion Criteria:

          -  severe symptomatic hyponatremia in need of intensive care treatment

          -  non-hypotonic hyponatremia with plasma osmolality &gt;280 milliosmol (mOsm)/kg

          -  end of life care (palliative treatment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mirjam Christ-Crain, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mirjam Christ-Crain, Prof. MD</last_name>
    <phone>+41 61 265 50 78</phone>
    <email>mirjam.christ@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Refardt, MD</last_name>
    <phone>+41 61 328 76 08</phone>
    <email>julie.refardt@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Basel, Department of Endocrinology</name>
      <address>
        <city>Basel</city>
        <state>Basel Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Refardt, Dr., MD</last_name>
      <phone>+41 61 328 76 08</phone>
      <email>julie.refardt@usb.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 16, 2018</study_first_submitted>
  <study_first_submitted_qc>June 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Metadata describing the type, size and content of the datasets will be shared along with the study protocol and case report forms on the public repository dataverse.harvard.edu.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_url>http://dataverse.harvard.edu</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

